Cardio Diagnostics Holdings, Inc and Aimil Ltd Join Forces to Introduce Cardiovascular Epigenetic Technologies to India
17 10월 2023 - 10:01PM
Business Wire
Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of
artificial intelligence-driven precision cardiovascular medicine
tests, today announced a significant move to transform global
cardiovascular health, by entering into a Supply and Distribution
Agreement with one of India’s premier organizations, Aimil Ltd.
Aimil, a company at the forefront of the instrumentation industry
in India since 1932 with 14 sales and services offices across
India, is a leader in introducing innovative, best-in-class
technologies from around the world to their extensive healthcare
network throughout India.
Cardiovascular disease (CVD) remains the leading cause of death
in India, with the nation facing alarmingly high incidences.
According to the Global Burden of Disease study by the Institute
for Health Metrics and Evaluation, the age-standardized CVD death
rate in India is 282 deaths per 100,000 people, which is markedly
higher than the global average of 233 deaths per 100,000 people.
Studies have reported that Indians develop heart disease nearly a
decade earlier than their European counterparts, with approximately
62% of heart disease related deaths among Indians being premature.
This strategic venture between Cardio Diagnostics and Aimil seeks
to address the growing prevalence of heart disease in India through
the introduction of Cardio Diagnostics’ clinical test,
PrecisionCHD, for the detection and personalized management of
coronary heart disease (CHD).
The first phase of this collaboration will focus on
pre-marketing, laying the groundwork for a successful product
introduction to Aimil’s extensive healthcare network. Cardio
Diagnostics and Aimil intend to further expand the Supply and
Distribution Agreement after a successful phase one, to ensure that
customers in India have consistent and reliable access to Cardio
Diagnostics’ groundbreaking diagnostic test. With Cardio
Diagnostics’ PrecisionCHD test, there is a significant opportunity
to reduce the burden of CHD across India. Unlike current tests to
diagnose CHD such as a stress test and CCTA, PrecisionCHD does not
require costly infrastructure nor exposing a patient to radiation
or kidney-damaging contrast dye. PrecisionCHD only requires a
simple blood draw from the patient, allowing for this test to be
deployed at scale in both urban and rural settings.
“Heart disease is a global problem and Cardio Diagnostics’
expansion to India underscores our commitment to combat heart
disease globally. We are thrilled to partner with Aimil on our
first international expansion,” said Meesha Dogan Ph.D., CEO and
Co-Founder of Cardio Diagnostics. “This expansion is possible
because Cardio Diagnostics’ clinical tests are developed with
scalability in mind with respect to operations and costs, enabling
deployment across diverse healthcare landscapes worldwide, to play
a transformative role in mitigating heart disease globally.”
"We are excited to collaborate with Cardio Diagnostics to
introduce the first epigenetics-based heart disease diagnostic
technology to India. As a leader in the healthcare industry, Aimil
is committed to empowering our customers, partners, and the
healthcare community in India with innovative solutions to tackle
heart disease,” said Dr. Mallika Kapur, Executive Director of
Aimil.
About Cardio Diagnostics
Cardio Diagnostics is an artificial intelligence-powered
precision cardiovascular medicine company that makes cardiovascular
disease prevention, detection, and management more accessible,
personalized, and precise. The Company was formed to further
develop and commercialize clinical tests by leveraging a
proprietary Artificial Intelligence (AI)-driven Integrated
Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular
disease to become one of the leading medical technology companies
for improving prevention, detection, and treatment of
cardiovascular disease. For more information, please visit
www.cardiodiagnosticsinc.com.
About Aimil
Aimil was founded in 1932, with a mission to bring leading edge
technologies to India. With 14 sales and service offices across
India, 1000+ employees, NABL certified testing and calibration
laboratories, and manufacturing, R&D & software development
capability, Aimil offers value-added distribution to overseas
companies wanting to expand professionally in India.
www.aimil.com
Forward-Looking Statements
Certain statements and information included in this press
release constitute "forward-looking statements" within the meaning
of the Private Securities Litigation Act of 1995. When used in this
press release, the words or phrases “will”, "will likely result,"
"expected to," "will continue," "anticipated," "estimate,"
"projected," "intend," “goal,” or similar expressions are intended
to identify "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
are subject to certain risks, known and unknown, and uncertainties,
many of which are beyond the control of the Company. Such
uncertainties and risks include but are not limited to, our ability
to successfully execute our growth strategy, changes in laws or
regulations, economic conditions, dependence on management,
dilution to stockholders, lack of capital, the effects of rapid
growth upon the Company and the ability of management to
effectively respond to the growth and demand for products and
services of the Company, newly developing technologies, the
Company’s ability to compete, regulatory matters, protection of
technology, the effects of competition and the ability of the
Company to obtain future financing. An extensive list of factors
that can affect future results are discussed in the Current Report
on Form 10-K for the period ended December 31, 2022 and Form 10-Q
for the period ended March 31, 2023, under the heading “Risk
Factors” in Part I, Item IA thereof, and other documents filed from
time to time with the Securities and Exchange Commission. Such
factors could materially adversely affect the Company's financial
performance and could cause the Company's actual results for future
periods to differ materially from any opinions or statements
expressed within this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231017212908/en/
Investors: Gene Mannheimer Investor Relations 855-226-9991
investors@cardiodiagnosticsinc.com
Media & Public Relations: Khullani Abdullahi 855-226-9991
pr@cardiodiagnosticsinc.com
Cardio Diagnostics (NASDAQ:CDIO)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Cardio Diagnostics (NASDAQ:CDIO)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024